A Phase 3 Study of Volrustomig (MEDI5752) in Combination With Carboplatin Plus Pemetrexed in Inoperable Pleural Mesothelioma

Full Title

A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed Versus Platinum plus Pemetrexed or Nivolumab plus Ipilimumab in Participants with Unresectable Pleural Mesothelioma (eVOLVE-Meso) (WCG IRB)

Purpose

In this study, researchers are comparing a new combination drug treatment with other standard treatments for pleural mesothelioma. The people in this study have mesothelioma which started in the pleura (lining of the lung) and is inoperable (cannot be taken out with surgery). Moreover, they have not yet received anti-cancer therapy for their mesothelioma.

If you join this study, you will be randomly assigned to get one of these treatments:

• Volrustomig (MEDI5752, the study drug) with carboplatin and pemetrexed
• Pemetrexed with either cisplatin or carboplatin
• Nivolumab plus ipilimumab immunotherapy

These medications are given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

• Have advanced inoperable pleural mesothelioma which has not yet been treated.
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Michael Offin’s office at 646-608-3763.